Illumina (ILMN) Stock Forecast & Price Target

$129.52

+0.34 (+0.26%)

(As of 09/16/2024 ET)

Illumina - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 23 Analyst Ratings

Based on 23 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 1 has given a sell rating, 9 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for ILMN.

Consensus Price Target

$151.05
16.62% Upside

High Forecast	$242.00
Average Forecast	$151.05
Low Forecast	$100.00

According to the 23 analysts' twelve-month price targets for Illumina, the average price target is $151.05. The highest price target for ILMN is $242.00, while the lowest price target for ILMN is $100.00. The average price target represents a forecasted upside of 16.62% from the current price of $129.52.

Type	Current Forecast 9/17/23 to 9/16/24	1 Month Ago 8/18/23 to 8/17/24	3 Months Ago 6/19/23 to 6/18/24	1 Year Ago 9/17/22 to 9/17/23
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)
Hold	9 Hold rating(s)	9 Hold rating(s)	11 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$151.05	$151.10	$158.14	$236.05
Forecasted Upside	16.62% Upside	26.24% Upside	24.30% Upside	23.73% Upside

Introducing the Perceptron (Ad)

On Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.

Just click here to register.

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Illumina Stock vs. The Competition

Type	Illumina	Medical Companies	S&P 500
Consensus Rating Score	2.57	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	15.71% Upside	1,086.00% Upside	8.07% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/28/2024	Argus 3 of 5 stars	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+14.59%
8/16/2024	Daiwa America 0 of 5 stars	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/16/2024	Daiwa Capital Markets 1 of 5 stars		Upgrade	Neutral ➝ Buy	$120.00 ➝ $154.00	+19.57%
8/15/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Outperform ➝ Sector Outperform	$176.00 ➝ $164.00	+27.33%
8/14/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$242.00 ➝ $242.00	+96.91%
8/14/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brennan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$126.00 ➝ $144.00	+20.28%
China Stockpiling Gold “Like No Tomorrow” (Ad) For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide.
8/14/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$125.00	+4.41%
8/13/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$200.00 ➝ $195.00	+56.58%
8/7/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$140.00 ➝ $155.00	+27.77%
8/7/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$130.00 ➝ $125.00	+5.03%
8/7/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$119.00 ➝ $124.00	-3.16%
8/7/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$131.00 ➝ $133.00	+4.90%
7/10/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$170.00 ➝ $170.00	+59.36%
6/11/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$195.00 ➝ $175.00	+59.35%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$115.00	+10.28%
3/20/2024	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Positive ➝ Mixed
1/16/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
12/15/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform
12/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$155.00	+22.37%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$175.00	+48.76%
12/12/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$140.00 ➝ $100.00	-14.99%
11/10/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$210.00 ➝ $120.00	+22.17%
10/12/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$200.00	+49.91%
8/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$225.00 ➝ $200.00	+8.41%
2/8/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Souda Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$249.00 ➝ $250.00	+15.88%
1/10/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$350.00 ➝ $296.00	+42.78%
11/7/2022	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight	$240.00 ➝ $225.00	+3.19%
11/4/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$327.00 ➝ $350.00	+65.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:29 PM ET.

ILMN Forecast - Frequently Asked Questions

What is Illumina's forecast for 2024?: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $151.05, with a high forecast of $242.00 and a low forecast of $100.00.
Should I buy or sell Illumina stock right now?: 23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There is currently 1 sell rating, 9 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ILMN shares.
Does Illumina's stock price have much upside?: According to analysts, Illumina's stock has a predicted upside of 25.64% based on their 12-month stock forecasts.
Has Illumina been upgraded by Wall Street analysts recently?: Over the previous 90 days, Illumina's stock had 6 upgrades by analysts.
What analysts cover Illumina?: Illumina has been rated by research analysts at Argus, Barclays, Citigroup, Daiwa America, Daiwa Capital Markets, JPMorgan Chase & Co., Piper Sandler, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stephens, TD Cowen, and UBS Group in the past 90 days.
Do Wall Street analysts like Illumina more than its competitors?: Analysts like Illumina less than other "medical" companies. The consensus rating score for Illumina is 2.57 while the average consensus rating score for "medical" companies is 2.77. Learn more on how ILMN compares to other companies.